본문 바로가기
KERD
논문KCI 등재

외적 환경을 고려한 최적의 항우울제 치료

Optimising Antidepressant Use in Clinical Practice : Considering External Factors

한창환|함병주
대한신경정신의학회 (Korean Neuropsychiatric Association)|2008.01|신경정신의학 (JOURNAL OF THE KOREAN NEUROPSYCHIATRIC ASSOCIATION)|제47권 제1호|pp. 22-27

0

조회

0

다운로드

3

인용

0

참고문헌

키워드

우울증·항우울제·최적 치료.Depresion· Antidepresants· Optimal treatment.
주제분류정신과학

초록

Depressive illness is a major public health problem with important medical, social and economic implications. The efficacy of various antidepressants in treating depression has been demonstrated in randomized controlled trials (RCTs). However, these studies do not adequately address the complexities of clinical practice. Although most of RCTs assumed there was no difference in efficacy between the tricyclic antidepressants (TCAs) and serotonin specific reuptake inhibitors (SSRIs), naturalistic studies show that patients who take TCAs often receive subtherapeutic doses for inadequate duration than those with SSRIs. Because the benefits of the implementation of current guidelines are limited, the optimal choice of medication must be guided by detailed history and careful consideration of the real-world efficacy of antidepressants and long-term health care costs. (J Korean Neuropsychiatr Assoc 2008;47(1):22-27)

Abstract

Depressive illness is a major public health problem with important medical, social and economic implications. The efficacy of various antidepressants in treating depression has been demonstrated in randomized controlled trials (RCTs). However, these studies do not adequately address the complexities of clinical practice. Although most of RCTs assumed there was no difference in efficacy between the tricyclic antidepressants (TCAs) and serotonin specific reuptake inhibitors (SSRIs), naturalistic studies show that patients who take TCAs often receive subtherapeutic doses for inadequate duration than those with SSRIs. Because the benefits of the implementation of current guidelines are limited, the optimal choice of medication must be guided by detailed history and careful consideration of the real-world efficacy of antidepressants and long-term health care costs. (J Korean Neuropsychiatr Assoc 2008;47(1):22-27)

참고문헌 (56)

  1. Chung S, "Does the use of SSRIs reduce medical care utilization and expenditures?", J Ment Health Policy Econ, 8, pp.119~129 (2005)
  2. Greenberg PE, "The economic burden of depression in 1990", J Clin Psychiatry, 54, pp.405~418 (1990)
  3. Greenberg PE, "Depression: a neglected major illness", J Clin Psychiatry, 54, pp.419~424 (1993)
  4. Prien RF, "Continuation drug therapy for major depressive episodes: how long should it be maintained?", Am J Psychiatry, 143, pp.18~23 (1986)
  5. Blacker CV, "Depressive disorder in primary care", Br J Psychiatry, 150, pp.737~751 (1987)
  6. Paykel ES, "Recognition and management of depression in general practice: consensus statement", BMJ, 305, pp.1198~1202 (1992)
  7. Weich S, "Somatic presentation of psychiatric morbidity in general practice", Br J Gen Pract, 45, pp.143~147 (1995)
  8. Lépine JP, "Depression in the community: the first pan-European study DEPRES (Depression Research in European Society)", Int Clin Psychopharmacol, 12, pp.19~29 (1997)
  9. Mendlewicz J, "Optimising antidepressant use in clinical practice: towards criteria for antidepressant selection", Br J Psychiatry Suppl, 42, pp.1~3 (2001)
  10. Pampallona S, "Patient adherence in the treatment of depression", Br J Psychiatry, 180, pp.104~109 (2002)
  11. Demyttenaere K, "Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events", J Clin Psychiatry, 62(22), pp.30~33 (2001)
  12. Fawcett J, "Compliance: definitions and key issues", J Clin Psychiatry, 56(1), pp.4~8 (1995)
  13. Cramer JA, "Enhancing medication compliance for people with serious mental illness", J Nerv Ment Dis, 187, pp.53~55 (1999)
  14. Donoghue J, "Antidepressant use in clinical practice: efficacy v. effectiveness", Br J Psychiatry Suppl, 42, pp.9~17 (2001)
  15. Anderson IM, "Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology", J Psychopharmacol, 14, pp.3~20 (2000)
  16. Zetin M, "Rational antidepressant selection: applying evidence-based medicine to complex real-world patients", Psychopharmacol Bull, 39, pp.38~104 (2006)
  17. Arroll B, "Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis", Ann Fam Med, 3, pp.449~456 (2005)
  18. Zetin M, "Rational antidepressant selection", Compr Ther, 20, pp.209~223 (1994)
  19. Simon G, "Cost-effectiveness comparisons using “real world” randomized trials: the case of new antidepressant drugs", J Clin Epidemiol, 48, pp.363~373 (1995)
  20. Zimmerman M, "Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?", Am J Psychiatry, 159, pp.469~473 (2002)
  21. "Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association", Am J Psychiatry, 157, pp.1~45 (2000)
  22. Hughes CW, "The Texas Children’s Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder", J Am Acad Child Adolesc Psychiatry, 38, pp.1442~1454 (1999)
  23. Altshuler LL, "The Expert Consensus Guideline Series. Treatment of depression in women", Postgrad Med, pp.1~107 (2001)
  24. Thase ME, "Effectiveness of antidepressants: comparative remission rates", J Clin Psychiatry, 64(2), pp.3~7 (2003)
  25. Donoghue JM, "The treatment of depression: prescribing patterns of antidepressants in primary care in the UK", Br J Psychiatry, (168), pp.164~168 (1996)
  26. Donoghue J, "Sub-optimal use of tricyclic antidepressants in primary care", Acta Psychiatr Scand, 98, pp.429~431 (1998)
  27. Dunn RL, "Longitudinal patterns of antidepressant prescribing in primary care in the UK: comparison with treatment guidelines", J Psychopharmacol, 13, pp.136~143 (1999)
  28. Scott J, "Chronic depression", Br J Psychiatry, 153, pp.287~297 (1988)
  29. Altamura AC, "The use of antidepressants for long-term treatment of recurrent depression: rationale, current methodologies, and future directions", J Clin Psychiatry, 54, pp.29~37 (1993)
  30. Hylan TR, "SSRI antidepressant drug use patterns in the naturalistic setting: a multivariate analysis", Med Care, 37, pp.36~44 (1999)
  31. Sturm R, "How can care for depression become more costeffective?", JAMA, 273, pp.51~58 (1995)
  32. Melfi CA, "The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression", Arch Gen Psychiatry, 55, pp.1128~1132 (1998)
  33. MacDonald TM, "Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland", BMJ, 313, pp.860~861 (1996)
  34. "Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group", Psychopharmacology(Berl), 90, pp.131~138 (1986)
  35. "Paroxetine. a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group", J Affect Disord, 18, pp.289~299 (1990)
  36. Leon AC, "A 20-year longitudinal observational study of somatic antidepressant treatment effectiveness", Am J Psychiatry, 160, pp.727~733 (2003)
  37. Quitkin FM, "When should a trial of fluoxetine for major depression be declared failed?", Am J Psychiatry, 160, pp.734~740 (2003)
  38. Bagby RM, "Psychosocial and clinical predictors of response to pharmacotherapy for depression", J Psychiatry Neurosci, 27, pp.250~257 (2002)
  39. Szegedi A, "Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression", J Clin Psychiatry, 64, pp.413~420 (2003)
  40. Rost K, "Managing depression as a chronic disease: a randomised trial of ongoing treatment in primary care", BMJ, 325, pp.934~ (2002)
  41. Hemels ME, "Increased use of antidepressants in Canada: 1981-2000", Ann Pharmacother, 36, pp.1375~1379 (2000)
  42. Song F, "Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability", BMJ, 306, pp.683~687 (1993)
  43. Hatziandreu EJ, "Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin", Pharmacoeconomics, 5, pp.249~268 (1994)
  44. Einarson TR, "A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders", Clin Ther, 17, pp.136~153 (1995)
  45. Doyle JJ, "A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs", Value Health, 4, pp.16~31 (2001)
  46. Simon GE, "Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants", JAMA, 275, pp.1897~1902 (1996)
  47. Hosák L, "Costs and outcomes of use of amitriptyline, citalopram and fluoxetine in major depression: exploratory study", Acta Medica(Hradec Kralove), 43, pp.133~137 (2000)
  48. Kendrick T, "Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial", Br J Psychiatry, 188, pp.337~345 (2006)
  49. Priest RG, "Cost-effectiveness of venlafaxine for the treatment of major depression in hospitalized patients", Clin Ther, 18, pp.347~358 (1996)
  50. Trivedi MH, "Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder", J Clin Psychopharmacol, 24, pp.497~506 (2004)
  51. Demyttenaere K, "A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium", Clin Ther, 27, pp.111~124 (2005)
  52. Llorca PM, "Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation", Int J Clin Pract, 61, pp.702~710 (2007)
  53. François C, "A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway", Eur J Health Econ, 4, pp.12~19 (2003)
  54. Stewart A, "Choosing an antidepressant: effectiveness based pharmacoeconomics", J Affect Disord, 48, pp.125~133 (1998)
  55. Simon G, "Health care costs associated with depressive and anxiety disorders in primary care", Am J Psychiatry, 152, pp.352~357 (1995)
  56. Kwon JS, "How to choose the antidepressants in clinical practice?", Koean J Psychopharmacol, 11, pp.3~6 (2000)

관련 논문AI추천

근거중심 한국형 우울증 약물학적 치료지침, 개정판 (I) : 항우울제 치료의 초기선택고영훈, 박선철, 박용천, 백종우, 성승환, 심세훈, 오강섭, 원은수, 이강준, 이문수, 이민수, 이화영, 이희영, 전홍진, 최준호, 한규만, 한상우, 한창수, 함병주, 황태연대한신경정신의학회 · 신경정신의학2013 · 제52권 제4호근거중심 한국형 우울증 약물학적 치료지침, 개정판(II) : 항우울제의 위약대비 효과, 항우울제간 효과차이 및 효과판정의 적정시점고영훈, 구재우, 박선철, 박용천, 백종우, 성승환, 심세훈, 오강섭, 원은수, 이강준, 이경민, 이문수, 이민수, 이화영, 전홍진, 최준호, 한규만, 한상우, 한창수, 함병주, 황태연대한신경정신의학회 · 신경정신의학2013 · 제52권 제5호Antidepressant Prescribing Patterns in Korea: Results from the Clinical Research Center for Depression Study김성완, 김재민, 배경열, 신일선, 윤진상, 이민수, 임현우, 전태연, 정성원대한신경정신의학회 · PSYCHIATRY INVESTIGATION2011 · 제8권 제3호근거중심 한국형 우울증 약물학적 치료지침, 개정판(III) : 항우울제의 증량, 교체, 병합 및 강화요법고영훈, 구재우, 박선철, 박용천, 백종우, 성승환, 심세훈, 오강섭, 원은수, 이강준, 이경민, 이문수, 이민수, 이화영, 이희영, 전홍진, 최준호, 한규만, 한상우, 한창수, 함병주, 황태연대한신경정신의학회 · 신경정신의학2013 · 제52권 제5호왜 다양한 항우울제가 필요한가?김용구, 윤호경대한신경정신의학회 · 신경정신의학2008 · 제47권 제1호노년기 우울증에서의 항우울제 치료에 대한 고찰박상진, 윤지호대한노인정신의학회 · 노인정신의학2013 · 제17권 제1호

이 간행물의 다른 논문 (12건)

현대 정신의학은 어떻게 우울증을 이해하고 있나?김보라, 김찬형, 이상혁pp. 3-10왜 다양한 항우울제가 필요한가?김용구, 윤호경pp. 11-21정신분열병 환자의 사회인지 손상이 사회적 기능손상에 미치는 영향나명현, 이영호, 권준수, 노규식, 오정은, 강도형pp. 28-35한국판 Edinburgh Postnatal Depression Scale의 임상적 적용허지원, 오강섭, 신영철, 김계현, 김용구pp. 36-44간호사들에서 월경전불쾌기분장애와 삶의 질, 사회직업기능 및 장애 간의 연관성김재민, 윤진상, 김성완, 양수진, 신일선, 김선영, 김웅장pp. 45-51
원문 보기